Skip to content
Fiscal Receipts

Senate LDA lobbying filing

HUMANA INC

Registrant: HUMANA, INC. Year: 2024 Period: First Quarter Type: Q1

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$2.08M

Tracked program mentions1

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

  • Major Equipment, WHS31matched: “31PE code cited directly

    TRICARE Policy Issues including Telehealth, Value-Based Care, and T-5 Transition NDAA Implementation Policy Issues…

Lobbying activities4

  • DefenseDEF

    TRICARE Policy Issues including Telehealth, Value-Based Care, and T-5 Transition NDAA Implementation Policy Issues Veterans Healthcare and Policy Issues Implementation of National Defense Authorization Act for Fiscal Year 2024 Public Law No: 118-31

  • Medicare/MedicaidMMM

    Medicare Advantage (MA) Policy and Reimbursement Enactment of policies in Calendar Year (CY) 2024 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Medicare Part D Issues Medicaid Policy Issues Including Redeterminations and Dual Eligibles Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Home Health Policy and Reimbursement Issues Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 S. 3018/H.R. 3173, Improving Seniors Timely Access to Care Act (117th Congress) Prior Authorization Policy and Regulatory Issues CMS-4185-F2 Medicare Advantage Risk Adjustment Data Validation Final Rule Primary Care and Value-Based Care Policy and Reimbursement Clinical Policy Issues Including Workforce and Mental Health Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Plan Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly, and Health Information Technology Standards (CMS-4205-P) Calendar Year (CY) 2024 Home Health Prospective Payment System Final Rule (CMS-1780-F) Calendar Year (CY) 2024 Medicare Physician Fee Schedule Final Rule (CMS-1784-F) Hospital Outpatient Prospective Payment System (OPPS): Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule (CMS 1793-F) Fiscal Year (FY) 2025 Hospice Payment Rate Update Proposed Rule (CMS-1810-P) Fiscal Year (FY) 2025 Skilled Nursing Facility Prospective Payment System Proposed Rule (CMS 1802-P) Draft Calendar Year (CY) 2025 Part D Redesign Program Instructions Calendar Year (CY) 2025 Advance Notice for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs Medicare Prescription Payment Plan: Final Part One Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025, and Response to Relevant Comments Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025, and Solicitation of Comments CMS Interoperability and Prior Authorization final rule (CMS-0057-F)

  • PharmacyPHA

    Prescription drug pricing Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues

  • Taxation/Internal Revenue CodeTAX

    Tax Reform Implementation Issues

Lobbyists4

  • JEFFREY LUNGREN
  • RACHEL MAGNUSON
  • TIFFANY HAVERLYrevolving door

    Rep. Adrian Smith, Dep. COS/Sr. Advr.; Comms. Dir./Sr. Advr. Rep. Kay Granger, Strat. Comms. Advr. Rep. Greg Walden, Comms. Dir. Rep. Phil Roe, Comms. Dir.; Leg/Press/Staff Asst.; Leg. Corr. Rep. David Davis, Staff Asst.

  • VERONICA JACKSON

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.